ASCO 2017

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

By

There may be potential clinical benefits to performing hereditary cancer risk assessments and multi-gene panel testing in patients with sarcoma.

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

By

PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes.

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

By

Talimogene laherparepvec plus ipilimumab improves the overall response rate over ipilimumab alone among patients with unresected, advanced melanoma.

In Focus: Abemaciclib for Advanced Breast Cancer

In Focus: Abemaciclib for Advanced Breast Cancer

By

Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

By

Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.

Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

By

The management of metastatic breast cancer resistant or refractory to hormonal treatments, while still challenging, is rapidly improving.

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

By

Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.

Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

By

Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.

Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck

Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck

By

Adding afatinib to standard CRT is not recommended for patients with primary unresected, high- or intermediate-risk HNSCC.

Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?

Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?

By

Although aldoxorubicin did not improve OS, the available evidence suggests that it is nevertheless superior to doxorubicin — particularly among patients with liposarcoma and leiomyosarcoma.

Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer

Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer

By

Patients with early stage, HER2-negative breast cancer may be sufficiently well-treated with docetaxel and cyclophosphamide instead of anthracycline-based chemotherapy.

Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer

Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer

By

Reducing the duration of androgen-deprivation therapy with radiation therapy from 36 months to 18 months is safe for patients with high-risk prostate cancer.

Engagement Is Survival: My Take on ASCO 2017

Engagement Is Survival: My Take on ASCO 2017

By

Don Dizon, MD: In addition to important clinical trial outcomes that evaluated novel strategies across tumor types, there were impressive studies aiming to help our patients live with cancer as well.

aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

By

An automated bone scan index at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate with bone metastases.

Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy

Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy

By

Only 21% of patients underwent IGHV mutation-testing prior to initiating bendamustine plus rituximab therapy; 46% of tested patients were IGHV-mutated.

Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials

Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials

By

In this question-and-answer session, Cancer Therapy Advisor asked Dr Duma about her team's study and minority patient representation in breast cancer studies.

Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN

Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN

By

Bevacizumab added to a standard platinum doublet chemotherapy regimen did not improve OS, though PFS was improved, among patients with cancer of the head and neck.

Pembrolizumab Active in Advanced Gastric Cancer

Pembrolizumab Active in Advanced Gastric Cancer

By

Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.

FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer

FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer

By

Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.

Intermittent Letrozole May Benefit Some Patients With Breast Cancer

Intermittent Letrozole May Benefit Some Patients With Breast Cancer

By

Study data suggest that some women with breast cancer may benefit from intermittent over continuous letrozole treatment.

Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD

Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD

By

Ulka Vaishampayan, MD, and Neeraj Agarwal, MD, spoke with Cancer Therapy Advisor about treatment recommendations for patients newly diagnosed with metastatic RCC.

Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment

Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment

By

Data from the BFORE study showed significantly higher 12-month major molecular remission and complete cytogenetic response with bosutinib.

High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer

High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer

By

Nivolumab alone or combined with ipilimumab provided durable responses in patients with advanced small-cell lung cancer whose disease progressed on prior platinum therapies.

Momelotinib for Previously Treated Patients With Myelofibrosis

Momelotinib for Previously Treated Patients With Myelofibrosis

By

For patients with primary or secondary myelofibrosis who have already received ruxolitinib, momelotinib was significant in improving disease-related symptoms over best available therapy.

Dabrafenib Plus Trametinib Promising in Melanoma

Dabrafenib Plus Trametinib Promising in Melanoma

By

Patients with BRAF V600E melanoma and brain metastasis showed intracranial responses when receiving a BRAF (dabrafenib) and a MEK inhibitor (trametinib).

Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer

Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer

By

Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.

Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer

Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer

By

An analysis suggested that a shorter, 3-month course of adjuvant chemotherapy for some patients with stage III colon cancer may yield comparable outcomes to the standard 6-month course.

Immunotherapy Shows Promise in Patients With Melanoma Brain Metastases

Immunotherapy Shows Promise in Patients With Melanoma Brain Metastases

By

Nivolumab alone or in combination with ipilimumab were reported to show activity in patients with melanoma and asymptomatic brain metastases.

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases

By

Combination immunotherapy with nivolumab and ipilimumab provided intracranial and extracranial responses for patients with melanoma and brain metastases.

Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer

Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer

By

Patients with a germline BRCA mutation were at a reduced risk for progression when treated with olaparib for HER2-metastatic breast cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs